Earlier this month, the FDA approved Amneal Pharmaceuticals’ investigational agent IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules, as a treatment for patients with Parkinson disease (PD). Marketed as Crexont, the therapy is an oral formulation CD/LD which includes immediate-release granules as well as extended-release pellets. In its announcement, Amneal noted it expects the oral treatment to be available to patients in the United States in September 2024.
Significance of Newly Approved IPX203 for... - Cure Parkinson's
Significance of Newly Approved IPX203 for Parkinson Disease
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
So now it’s about the cost. If people can’t afford it or if in the UK the cost benefit analysis means it cannot be universally prescribed, then ………..
who would it be available to thanks for sharing
I posted this info in another forum. The drug is also known as "Crexont".
What I can't find is what's so different about it compared to other controlled release L-Dopa products like Sinemet CR
Reading the info you'd be forgiven for thinking this was the first controlled release L-Dopa ever. In particular why have they benchmarked it against standard release rather than another CR product?
sounds just like Rytary
Very strange. I searched for Crexont vs Rytary, an article apeared, i could see the furst paragraph, but i couldnt get access. When i tried a second time, instead of the article, it said "page doesn't exist".
pdexpertinstitute.com/exten...
In my opinion, these pellet medications always have a wide standard deviation (SD) that is not shown in the above graphs (figure 3; there should be vertical lines above each point). It would have been important to know this SD data in order to understand if the response to the medication is the same for everyone or subjective.